Updated May 2026 · ClinicalTrials.gov
University of Utah
15 clinical trials · 15 recruiting · OTHER
University of Utah has 15 clinical trials registered on ClinicalTrials.gov, with 15 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About University of Utah\'s Trial Portfolio
University of Utah is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.
15 of University of Utah's 15 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
University of Utah's research footprint spans Metastatic Prostate Cancer (2 trials), Prostate Cancer (1), and Androgen Deprivation Therapy (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
Not Applicable is the largest single phase in University of Utah's portfolio at 53% of registered trials. The full phase breakdown appears in the sidebar.
Trials by University of Utah
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer...
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
People with prostate cancer may have a decreased quality of life due to the cancer itself and due to a lifesaving cancer treatment. Physical therapy, including regular exercise,...
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated...
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic...
Guided Meditation During Radiation Therapy for Brain Tumors
The goal of this interventional treatment study is to assess the anxiolytic effect of providing guided meditation during radiation treatment (RT) in patients with brain tumors....
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery...
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and...
Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis
The investigators will evaluate a new powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand whether this device allows adequate head range of...
PCMS Task After Moderate-to-severe Stroke
Researchers at the University of Pittsburgh are conducting a research study to see how combining brain, nerve, and hand stimulation affect hand movement after stroke. The primary...
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more...
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 3000 US live births, similar to the incidence seen within the Utah Birth Defects cohort. The diaphragmatic...
Maternal Mental Health Access - MaMa
This hybrid effectiveness-implementation project will allow the team to evaluate and refine implementation in preparation for future multisite trials to ultimately move the...
Circadian Intervention to Improve Cardiometabolic Health
The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a...
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino...
The goal of this clinical trial is to learn if the culturally adapted couples sleep health intervention (Nuestro Sueno) improves positive airway pressure use and sleep among...
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Progression of Early Atrophic Lesions
Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only...
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does University of Utah have on ClinicalTrials.gov?
University of Utah has 15 clinical trials registered on the federal ClinicalTrials.gov registry, of which 15 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does University of Utah study?
University of Utah's registered trials cover 20 conditions on ClinicalTrials.gov, led by Metastatic Prostate Cancer (2 trials), Prostate Cancer (1 trial), Androgen Deprivation Therapy (1 trial), Chronic Lymphocytic Leukemia (1 trial), Small Lymphocytic Lymphoma (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a University of Utah clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-05-08 · 15 trials tracked for University of Utah.
For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.